Effect of riboflavin supplementation on blood pressure and possible effect modification by the MTHFR C677T polymorphism: a randomised trial in rural Gambia
Open Access
- 24 August 2020
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 1034
Abstract
Introduction: Emerging evidence links a functional polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene (rs1801133) with hypertension in adults. This variant reduces the affinity of MTHFR for its cofactor flavin-adenine dinucleotide (FAD) which is derived from riboflavin. Previous work has demonstrated a blood pressure (BP)-lowering effect of riboflavin in Irish adults with the MTHFR 677TT variant. We hypothesize that the almost-universal severe riboflavin deficiency seen in rural Gambia mimics the BP phenotypic effect of the TT variant and exacerbate the effect of the CT variant. We will test this in a randomised, placebo-controlled trial, whether intervention with riboflavin can decrease BP in adults in rural Gambia. Methods: This is a phase 2 recall-by-genotype randomised single-blind placebo-controlled riboflavin supplementation trial. We will use the Keneba biobank to recruit approximately 102 individuals aged between 18-70, previously genotyped for the MTHFR C677T polymorphism and identified as carrying the T allele; these individuals will be age- and sex-matched to a similar number of homozygotes for the C allele. The participants will be randomised to a 16-week supplementation trial of 5 mg/day riboflavin or placebo, supplied every 14 days. The primary outcome, BP, will be measured at baseline and at weeks 8 and 16. Blood samples, collected at baseline and week 16, will be analysed for riboflavin, homocysteine, red cell folate, cobalamin (vitamin B12) and pyridoxine (vitamin B6). Discussion: The study will evaluate the role of riboflavin supplementation in BP control within a population with high levels of riboflavin deficiency and will test a possible gene-nutrient interaction with the MTHFR C677T polymorphism. If improvements in BP are observed in this study, and proven in subsequent large-scale interventions, riboflavin could offer a cost-effective, safe and accessible option for the prevention and control of hypertension in this population. Trial registration: ClinicalTrials.gov Identifier NCT03151096. Registered on 12 May 2017.Keywords
Funding Information
- African Partnership for Chronic Disease Research
This publication has 13 references indexed in Scilit:
- High blood pressure and associated risk factors as indicator of preclinical hypertension in rural West AfricaMedicine, 2017
- Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertensionMolecular Aspects of Medicine, 2017
- Cohort Profile: The Kiang West Longitudinal Population Study (KWLPS)—a platform for integrated research and health care provision in rural GambiaInternational Journal of Epidemiology, 2015
- Associations of MTHFR Gene Polymorphisms with Hypertension and Hypertension in Pregnancy: A Meta-Analysis from 114 Studies with 15411 Cases and 21970 ControlsPLOS ONE, 2014
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2013
- Blood Pressure in Treated Hypertensive Individuals With theMTHFR677TT Genotype Is Responsive to Intervention With RiboflavinHypertension, 2013
- Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-upThe American Journal of Clinical Nutrition, 2012
- Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFRJournal Of Hypertension, 2010
- Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductaseProceedings of the National Academy of Sciences, 2001
- Studies on micronutrient intakes and requirements in The GambiaJournal of Human Nutrition and Dietetics, 1989